Exclusive

Publication

Byline

Location

Singapore Clinical Trial: A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate... Read More


Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants with Obesity or Overweight who are Otherwise Healthy.

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate th... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy o... Read More


Singapore Clinical Trial: A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, mu... Read More


Singapore Clinical Trial: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab ... Read More


Singapore Clinical Trial: ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Comp... Read More


Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared with Pembrolizumab monotherapy in participants with advanced colorectal adenocarcinoma (CRC) harboring microsatellite instability (MSI) and/or deficient mismatch repair (DMMR)

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared wi... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC 9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherap... Read More


Singapore Clinical Trial: A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants with Obesity or Overweight

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Stu... Read More


Singapore Clinical Trial: A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating the safety and tolerability of ARD001 in healthy adult subjects and a Phase 2 open-label, multiple-dose study in adult subjects with hemophilia A

Singapore, Aug. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating t... Read More